Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness and caused by autoantibodies that bind to functional membrane proteins at the neuromuscular junction. Most patients have autoantibodies to the acetylcholine receptor (AChR), but a subset of patients instead have autoantibodies to muscle specific tyrosine kinase (MuSK). MuSK is an essential component of the Agrin/Lipoprotein receptor-related protein 4(LRP4)/MuSK/downstream of tyrosine kinase 7 (DOK7) pathway that is responsible for synaptic differentiation, including clustering of AChRs at the neuromuscular junction, both during development and in adult muscle. Nerve-released Agrin binds to LRP4 which then binds to MuSK, stimulating autophosphorylation and recruitment of DOK7 to complete the membrane component of the pathway. Serum-derived IgG4 subclass MuSK autoantibodies prevent the binding of LRP4 to MuSK, subsequently impairing autophosphorylation, resulting in the loss of Agrin-induced AChR clustering in the mouse myotube-forming C2C12 line. Although this autoimmune mechanism appears well understood, MuSK autoantibodies from patients are polyclonal. Most are IgG4 but IgG1, 2 and 3 are also present and can achieve similar results on AChR clustering. In addition, most bind the first Ig-like domain in MuSK, however some patients harbor serum autoantibodies that recognize other domains in MuSK. We sought to establish individual MuSK IgG clones so that the disease mechanisms could be better understood. We isolated MuSK autoantibody-expressing B cells from MuSK MG patients with a fluorescenttagged MuSK antigen multimer and generated a panel of human monoclonal autoantibodies (mAbs) from these cells. We produced 77 mAbs from single B cells collected from six MuSK MG patients. Here we focused on three highly specific mAbs that bound quantitatively to MuSK in solution, to MuSK-expressing HEK cells and at mouse neuromuscular junctions where they colocalized with AChRs. These three IgG isotype mAbs (two IgG4 and one IgG3 subclass) recognized the Ig-like domain 2 of MuSK. The three MuSK mAbs inhibited Agrin induced-AChR clustering in C2C12 myotubes, but intriguingly, they enhanced rather than inhibited MuSK phosphorylation. This approach for ex vivo isolation of MuSK MG autoantibody-producing cells and production of human recombinant mAbs has identified distinct autoantibody specificities and likely divergent effector mechanisms. Collectively, these findings will enable a better understanding of MuSK autoantibody-mediated pathology.
Introduction
Patients with myasthenia gravis (MG) experience skeletal muscle weakness, worsened by activity. Typically, they present with ocular muscle weakness which then generalizes to involve limb muscles and, particularly, bulbar and respiratory muscles (1, 2) . The molecular immunopathology of MG is directly attributed to the presence of circulating autoantibodies specifically targeting extracellular domains of functional postsynaptic membrane proteins at the neuromuscular junction (NMJ) (1, 3) . The disease has multiple subtypes, defined by different autoantibody targets (4) (5) (6) (7) . Autoantibodies to the acetylcholine receptor (AChR), present in around 85% of patients, are mainly IgG1 and cause loss of AChRs via divalent binding, leading to internalization of AChRs and complement-mediated damage to the NMJ (1, 8) . Some of the 15% of patients without AChR autoantibodies have, instead, autoantibodies to muscle-specific kinase (MuSK) (7) or less commonly Lipoprotein receptor-related protein 4 (LRP4) (9, 10) . The MuSK autoantibody form of MG can be severe as it usually involves mainly bulbar muscles (11) , affecting speaking, chewing, swallowing, and breathing, and can cause permanent muscle atrophy over time (12, 13) . MuSK autoantibodies are particularly interesting because they are predominantly (14) of the non-complement activating IgG4 subclass; a subclass that can be functionally monovalent for antigen binding and hence does not cross-link its antigen (15) . Yet MuSK autoantibodies are demonstrably pathogenic, which can be established by passive transfer of the human disease phenotype to mice by injection of patients' IgG, or active immunization with MuSK (16) (17) (18) .
MuSK is an essential component of the Agrin/ LRP4/MuSK/downstream of tyrosine kinase 7 (DOK7) pathway that is responsible for clustering of AChRs at the NMJ, both during development and in mature muscle (19) . Serum-derived MuSK autoantibodies recognize mainly the N-terminal Ig-like domain 1 of MuSK, and prevent the binding of LRP4 to MuSK (20) (21) (22) . As a result, autophosphorylation of MuSK is inhibited and DOK7 is not recruited to complete the pathway. These effects can be demonstrated in the mouse myotube-forming C2C12 cell line, where MuSK autoantibodies prevent Agrin/LRP4-induced clustering of AChRs. In this model, isolated antigen binding fragments (Fabs) from MuSK-specific antibodies are sufficient to inhibit AChR clustering (23) . By contrast, AChR autoantibodies require divalent binding in order to cause loss of AChRs (8, 24, 25) . Although some of the mechanisms underlying MuSKautoantibody-associated MG appear well understood, patients' autoantibodies are heterogeneous. For instance, IgG1, 2 and 3 MuSK autoantibodies exist in most patients and their pathogenic mechanisms have not been well studied. Moreover, it is unclear whether autoantibodies to domains other than the first Ig-like domain in MuSK may contribute to disease.
We sought to establish individual MuSK IgG clones so that the mechanisms in this disease could be better analyzed both in vitro and in vivo.
All forms of MG improve with immunotherapies, but B cell depletion with a therapeutic monoclonal antibody (rituximab) against the B cell marker CD20 leads to substantial reductions in MuSK autoantibodies and relatively quick clinical improvement (11, 26, 27) . The success of anti-CD20 therapy suggests that the autoantibodies are derived from circulating MuSK-specific B cells rather than bone marrow resident long-lived plasma cells (LLPCs). LLPCs, which produce the vast majority of circulating antibody, express negligible levels of CD20 and thus are not targets of rituximab treatment (28) . This is confirmed by unchanged serum immunoglobulin and vaccine-specific titers post-treatment (26, 29, 30) . Accordingly, we proposed a speculative model in which an autoreactive fraction of memory B cells and circulating short-lived plasmablasts are responsible for much of the MuSK autoantibody production (3, 31) and recently demonstrated that circulating plasmablasts do indeed contribute to MuSK MG autoantibody production (32).
Given the accessibility of circulating autoantibody-producing cells, we adapted a previously reported approach (33) to produce a high-avidity fluorescent-tagged MuSK tetramer that could identify and assist in sorting rare autoantibody-expressing B cells from patient-derived blood samples. The specificity of the isolation was validated by single-cell sorting of antigen-labeled B cells and by reconstruction of recombinant human monoclonal antibodies, which were then tested for binding to MuSK.
Methods

Study Approval.
This study was approved by the Human Investigation Committee at the Yale School of Medicine. Informed consent was obtained from all subjects.
Isolation of serum and PBMC from MuSK MG patients. Peripheral blood samples were obtained from two healthy donors (HD1-2) and six patients (MuSK1-6) with autoantibody and clinically confirmed MuSK MG. Patients showed typical clinical and serological features of MuSK MG ( Table 1) . PBMCs were isolated by Ficoll separation and stored in liquid nitrogen until use, using a described protocol (34). Time-locked serum specimens were also obtained.
MuSK multimer generation.
The extracellular domain of MuSK was cloned into the pMT/Bip/His-A vector. The C-terminal region contained a short, flexible linker followed by the a BirA site (amino acids: GLNDIFEAQKIEWHE), downstream of which was a thrombin-cleavable (amino acids: LVPRGS) 6x histidine-tag. Protein expression was induced in S2 Drosophila cells.
Culture supernatant was collected and MuSK protein was purified using cobalt resin beads (Thermo scientific) according to the manufacturer's instructions. For tetramer formation, MuSK protein was biotinylated by incubation with BirA enzyme at a 1:100 molar ratio overnight at 4 °C in a buffer containing 50 mM tris, 50 mM bicine pH 8.3, 10 mM magnesium acetate, 10 mM adenosine-5'-triphosphate and 50 μM biotin. Excess biotin was removed using a 10kDa MWCO Slide-A-Lyzer dialysis cassette (Thermo scientific). Fluorescent multimers were formed using stepwise addition of allophycocyanin (APC)-conjugated streptavidin (Invitrogen) to biotinylated MuSK until a 1:4 molar ratio was reached.
Flow cytometry and cell sorting. For sorting MuSK multimer reactive B cells, B cells were enriched from PBMCs using negative-selection beads (Stemcell Technologies). They were incubated with live/dead stain, then stained with 20 μg/ml MuSK multimer on ice for 30 min.
Cells were then co-stained (using manufacturer's recommended dilutions) with fluorescently labeled antibodies against CD3 (Invitrogen, Pacific orange; UCTH1), CD14 (Invitrogen, Pacific orange; TUK4), CD19 (BD Biosciences, PE Cy7; SJ25C1), CD27 (BD Biosciences, PE; M-T271), and CD38 (BD Biosciences, V450; HB7) before sorting on a FACSaria (BD Biosciences) Immunofluorescence mouse muscle sections. The binding of the different human mAbs was analyzed by immunofluorescence using cryosections of mouse tibialis anterior muscles.
Muscles were cut longitudinally at 10 µm thickness on a Leica CM3050 S cryostat; sections were mounted on gelatin-coated glass slides and stored at −80 °C. After thawing, cryosections were fixed with 4% PFA for 10 min at room temperature and then blocked for 30 min with 2% bovine serum albumin. Sections were incubated for 1 hr at room temperature with one of the different human mAbs (1.5 µg/mL each), combined with Alexa-647-conjugated alpha- AChR clustering assay. The AChR clustering assay was performed as described (7) . Briefly, Statistics. AChR clustering on the C2C12 cells and MuSK tyrosine phosphorylation were analyzed using a one-way ANOVA with Dunnett's correction. Statistics were performed on GraphPad Prism (version 7.0a) software.
Results
Study subjects.
Patients (n=6, all female, mean age 44 ± 12 years (range 37-63), consistent with reported (47-49) demographics of MuSK MG) with laboratory and clinically confirmed MuSK autoantibodypositive MG were selected for study. Their clinical severity and serum autoantibody status at the time of sampling are summarized in Table 1 . The controls included two healthy individuals, one male aged 37 years and one female aged 30 years ( Table 1) . Both had no history of autoimmune disease and no recent inflammatory events and were negative for serum MuSK autoantibodies.
Generation of a multimeric, fluorescent MuSK antigen.
We expressed the extracellular domain of MuSK, which was tagged, at the C-terminus, with a
BirA site that allows for post-translational biotinylation. The addition of allophycocyanin (APC)- 
Identification and isolation of MuSK-specific B cells using labelled antigen.
We recently demonstrated (32) that MuSK autoantibody-producing cells can be identified in the circulation. Thus, we utilized the multimerized, labeled MuSK to enrich for such antigen-specific 
Screening of recombinant human monoclonal antibodies.
We cloned and expressed human recombinant mAbs from single sorted B cells or plasmablasts, which were positive for staining with the fluorescent MuSK multimer. We cloned 77 mAbs from the six MuSK MG patients, which were derived from memory B cells or plasmablasts that recognized MuSK, and another 29 from the two healthy controls. For initial antigen specificity screening, all of the variable heavy chain domains were cloned into a human IgG1 subclass expression vector, irrespective of their native isotype or IgG subclass usage, which was not determined at this step. The variable light chain domains were cloned into either a kappa or lambda expression vector based on their native usage. We first screened the mAbs for MuSK binding at 10 µg/mL using a live cell-based assay (CBA). At this mAb concentration, many of the mAbs, including those from the healthy controls, showed binding. However, using a concentration of 1µg/mL, three mAbs (MuSK1A, MuSK1B and MuSK3B) from two patients During the MuSK-specific B cell sort, the FACS analyzer marked each cell in the scatter plot and its corresponding position in the 96 well plate (index-sorting). After the mAbs were expressed and their MuSK specificity validated on the CBA, the exact position of the cell on the scatter plot was determined and consequently its phenotype was assessed. With this approach, we determined ( was isolated from a single-cell sorted total plasmablast population (32), without the use of the MuSK multimeric antigen.
Isotype, IgG subclass usage and molecular properties of MuSK-specific recombinant monoclonal antibodies.
The native isotype and IgG subclass was determined using an additional PCR and sequencing step. The IgG4 subclass was used by the B cell that expressed mAb MuSK1A ( Table 2) , mAb MuSK1B was natively expressed using IgG3 and mAb MuSK3B was IgM ( Binding of the mAbs was tested over a range of concentrations using a live CBA. These tests demonstrated that binding could be detected with only 20 ng/mL for the IgG mAbs MuSK1A, MuSK1B and MuSK3-28 (Figure 2A, B ). An independent radio-immunoprecipitation assay Figure 2D ). Finally, we tested the mAbs on sections of mouse muscle tissue to determine whether they could recognize mouse MuSK. The mAbs that were highly positive in the CBA, using human MuSK, also bound to mouse NMJs where the mAbs closely colocalized with AChRs ( Figure 2E ). These data also demonstrated that the mAbs can recognize MuSK when presented in its native biological environment, an important requisite for future pathogenicity experiments in mouse-derived cells and disease models.
MuSK autoantibody epitope mapping.
The extracellular domain of MuSK is comprised of three Ig-like domains (Ig1, 2 
MuSK autoantibody-producing B cell phenotypes.
Four mAbs that bound to MuSK in a robust manner were successfully isolated from two unique patients, while three additional patient samples did not yield any strong MuSK-binding mAbs.
These results point toward the remarkable rarity of such cells in the circulation of patients, even though such patients were experiencing active disease and had conspicuous serum autoantibody titers at the time of specimen collection. The mAb MuSK1B was derived from a cell with a plasmablast-like phenotype, expressing both CD27 and high levels of CD38. This plasmablast, along with that which produced mAb MuSK3-28 (32), support the notion that this circulating short-lived cell-type contributes to MuSK MG immunopathology. We previously proposed (31) that these cells are either direct or indirect targets of CD20-mediated B cell depletion depending on whether they express CD20 or are continuously supplied by CD20-bearing cells.
The isolated cell which yielded mAb MuSK1A displayed a memory B cell-like phenotype. The finding of this cell type among MuSK autoantibody-producers suggests that immunological memory might have been established in the MuSK MG patient it was derived from. One can speculate that activated memory B cells, such as that which produced mAb MuSK1A, can provide a reservoir from which autoantibody-secreting plasmablasts originate. Given that memory B cells express CD20, their direct elimination by CD20-targeted therapy (rituximab) may be the mechanism by which this treatment effects remarkable serum autoantibody decline and excellent clinical response in patients.
The patient from whom this B cell was isolated had received rituximab, responded well, then relapsed and it was during this relapse that the sample was collected. It will be interesting to learn whether the memory B cell, producing mAb MuSK1A, was historic or recently generated.
Antibody repertoire sequencing, which accurately identifies B cell clones through their unique B cell receptor sequence, could provide such information through analysis of specimens collected prior to treatment, but these data were not available for this study. The identification of historical clones would indicate that they escape B cell depletion, then contribute to clinical relapse after the treatment is withdrawn. Evidence supporting this mechanism has been recently reported:
Tissue-resident vaccine-specific memory B cells, which are refractory to depletion, undergo revaccination-induced expansion during B cell repopulation following rituximab treatment (71) . On the other hand, de novo generation may be occurring which would point toward a fundamental defect in B cells that, once generated, can efficiently re-establish autoantibody production and consequently disease manifestation.
MuSK autoantibody IgG subclasses and epitope recognition.
The majority of MG patients have autoantibodies against the AChR, which belong predominantly to the IgG1 and IgG3 subclasses. These autoantibodies activate the complement system and can cross-link the AChR resulting in endocytosis. In contrast, serum MuSK autoantibodies are reported to be predominantly IgG4 (14, 72) ; this IgG subclass neither activates complement, nor efficiently cross-links antigens (15, 23 (14, 72) . However, one (MuSK1B) is from the IgG3 subclass. These findings present the opportunity to widen our understanding of MuSK autoantibody-mediated pathology.
In their divalent (and monospecific) form, which we tested here, the IgG4 (expressed with an 
Limitations.
Several important limitations require consideration. The first involves pathogenic contributions.
We have isolated B cells and plasmablasts that express MuSK autoantibodies, however the contribution they make to serum autoantibodies in the patients has not been established.
Empirical evidence demonstrating that individual B cells or plasmablasts contribute to the reservoir of pathogenic autoantibodies in the serum is required to establish that these cells effect the disease process. This can be achieved through leveraging the unique antibody sequences that identify a B cell clone. These sequences can be compared to those derived from a proteomic analysis of the serum autoantibody repertoire within the same patient. This approach has been performed in several studies which have shown close associations between the B cell and the immunoglobulin repertoire (76) and others that point toward more diversity in the serum immunoglobulins (77) . Three of the MuSK mAbs demonstrated pathogenic capacity in the AChR clustering assay. The same mAbs show agonistic activity in the MuSK phosphorylation assays. These findings using in vitro cellular models indicate that the mAbs are functionally active, but further study is required to more fully understand the mechanisms by which they might contribute to disease in vivo. Pathogenicity can be evaluated in vivo using well-established passive transfer models of MuSK MG (16, 17) . Not only will such in vivo studies further define the pathogenic capacity of the mAbs, they will provide additional insights, such as the effects on particular muscle groups. Finally, since IgG4 antibodies can be functionally monovalent as a result of Fab-arm exchange (23, 24) , experiments assessing pathogenic capacities of MuSK1A and MuSK3-28 in vitro and in vivo under functionally monovalent conditions will be required to more thoroughly understand how they impact immunopathology.
Broader implications of impact.
We anticipate that these human MuSK mAbs and the approach to their isolation will be recognized as highly valuable tools in future studies. First, these mAbs can be used to dissect the molecular mechanisms of MuSK autoantibody pathology through studying how they specifically interact with MuSK and influence changes at the NMJ. Such detailed molecular dissection of autoantibody structure can potentially provide information for the design of treatments (such as molecular decoys or cell-based therapies) that target the autoimmune response with precision. Second, novel, sustainable pre-clinical models can be developed that do not rely on rare and limited human MG-derived serum autoantibodies. Specifically, clinically relevant animal models are expected to be developed, based on the passive transfer of defined, MuSK mAbs that are identical to some of the patient autoantibodies and will be available in unlimited supply at constant quality. Third, the identification and isolation of rare MuSK mAb- 
Author contributions:
This study was originally conceived, then initiated and directed by KCO. RJN provided all characterized subject specimens and directed the clinical aspects of the study. KT produced the 22 tetramer. KT and PS performed the single cell isolation, mAb expression, mAb sequencing and cell-based antibody assays and interpreted those data. MC, DB and AV designed, performed, and interpreted the phosphorylation assays. MMD, PMM and ML designed and performed the murine muscle staining and interpreted those data. LJ, PW, SRI and AV performed the radioimmunoassays and interpreted those data. MF performed additional cell-based antibody assays and contributed to the C2C12 assays that were established and performed by PS. KT, with assistance from EB, built and tested the MuSK domain deletion constructs. Data were analyzed and interpreted by all authors. All authors contributed to manuscript editing after it was initially drafted by KCO and AV with input from PS and ML. Key contributions in editing were further provided by PS and ML. 
